Related Experiment Video
Updated: Feb 8, 2026

Mouse Model of Surgical Uterine Injury and Subsequent Pregnancy Outcomes
Published on: June 27, 2025
Inflammation-Induced Adverse Pregnancy and Neonatal Outcomes Can Be Improved by the Immunomodulatory Peptide
Valeria Garcia-Flores1,2,3,4, Roberto Romero1,2,5,6,7, Derek Miller1,2,3,8
1Perinatology Research Branch, Program for Perinatal Research and Obstetrics, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NICHD/NIH/DHHS, Detroit, MI, United States.
Insights
Exendin-4 (Ex4) treatment reduced preterm birth rates and improved neonatal outcomes in animal models by dampening maternal inflammation. This intervention shows promise for preventing adverse pregnancy and neonatal outcomes linked to inflammation.
Area of Science:
- Reproductive Biology
- Immunology
- Neonatal Medicine
Background:
- Preterm birth is a major global cause of infant illness and death.
- Inflammation is a known cause of preterm birth, necessitating interventions to reduce maternal and fetal inflammatory responses.
- Targeting inflammatory pathways may offer a novel strategy to prevent adverse pregnancy and neonatal outcomes.
Purpose of the Study:
- To investigate the effects of exendin-4 (Ex4) on maternal and fetal inflammatory responses and pregnancy outcomes in animal models.
- To determine if Ex4 can mitigate adverse outcomes associated with systemic maternal inflammation and fetal inflammation.
- To explore the immunomodulatory mechanisms of Ex4 in neonates exposed to maternal inflammation.
Main Methods:
- Animal models were used to simulate systemic maternal inflammation (lipopolysaccharide injection) and fetal inflammation (intra-amniotic LPS).
- Exendin-4 (Ex4) was administered to dams experiencing inflammation.
- Pregnancy outcomes, neonatal outcomes, cytokine profiles, and immune cell populations (macrophages, neutrophils, T cells) were analyzed.
Main Results:
- Systemic maternal inflammation caused severe maternal and mild fetal cytokine responses, while fetal inflammation caused mild maternal and severe fetal cytokine responses, both leading to adverse outcomes.
- Ex4 treatment modestly reduced preterm birth rates in both systemic and fetal inflammation models.
- Ex4 significantly improved neonatal outcomes in the systemic inflammation model, normalizing neonatal cytokine profiles and inducing beneficial immunomodulatory effects, including M2 macrophage polarization and increased anti-inflammatory neutrophils.
Conclusions:
- Dampening maternal systemic inflammation with Ex4 can improve pregnancy and neonatal outcomes.
- Ex4 demonstrates immunomodulatory effects, suggesting its potential as a therapeutic agent for preventing preterm birth and improving neonatal health in cases of maternal inflammation.
- Targeting maternal inflammation via interventions like Ex4 offers a promising strategy to enhance neonatal survival and well-being.
Abstract:
Preterm birth is the leading cause of neonatal morbidity and mortality worldwide. Inflammation is causally linked to preterm birth; therefore, finding an intervention that dampens maternal and fetal inflammatory responses may provide a new strategy to prevent adverse pregnancy and neonatal outcomes. Using animal models of systemic maternal inflammation [intraperitoneal injection of lipopolysaccharide (LPS)] and fetal inflammation (intra-amniotic administration of LPS), we found that (1) systemic inflammation induced adverse pregnancy and neonatal outcomes by causing a severe maternal cytokine storm and a mild fetal cytokine response; (2) fetal inflammation induced adverse pregnancy and neonatal outcomes by causing a mild maternal cytokine response and a severe fetal cytokine storm; (3) exendin-4 (Ex4) treatment of dams with systemic inflammation or fetal inflammation improved adverse pregnancy outcomes by modestly reducing the rate of preterm birth; (4) Ex4 treatment of dams with systemic, but not local, inflammation considerably improved neonatal outcomes, and such neonates continued to thrive; (5) systemic inflammation facilitated the diffusion of Ex4 through the uterus and the maternal-fetal interface; (6) neonates born to Ex4-treated dams with systemic inflammation displayed a similar cytokine profile to healthy control neonates; and (7) treatment with Ex4 had immunomodulatory effects by inducing an M2 macrophage polarization and increasing anti-inflammatory neutrophils, as well as suppressing the expansion of CD8+ regulatory T cells, in neonates born to dams with systemic inflammation. Collectively, these results provide evidence that dampening maternal systemic inflammation through novel interventions, such as Ex4, can improve the quality of life for neonates born to women with this clinical condition.
More Related Videos
09:50Experimental Methods for Testing the Effects of Neurotrophic Peptide, ADNF-9, Against Alcohol-induced Apoptosis during Pregnancy in C57BL/6 Mice
Published on: April 24, 2013
06:15Wet Chemistry and Peptide Immobilization on Polytetrafluoroethylene for Improved Cell-adhesion
Published on: August 15, 2016
Related Concept Videos
Inflammation
Peptide Bonds
Predicting Reaction Outcomes
Outcomes of Glycolysis
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...
Local Anesthetics: Adverse Effects
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...
Skeletal Muscle Relaxants: Adverse Effects
Unlike...